Moleculin BiotechMBRX
13F holders, Q2 2024 (June 30)16holders −3
1new positions
4sold out
$3.52avg. 13F price*
At the end of Q2 2024, 16 institutions reported holding Moleculin Biotech Inc. (MBRX) in their 13F filings, down 3 from Q1 2024. 1 opened new positions and 4 sold out. The largest holders were Armistice Capital, LLC ($549K), Vanguard Group Inc. ($297K) and LPL Financial LLC ($119K).
- Company
- Moleculin Biotech Inc.
- CUSIP
- 60855D309
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $119K |
| Exits | 4 | $3K |
All 13F filers, Q1 2024 → Q2 2024: 55,613 shares bought and 355 shares sold, net +55,258 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Armistice Capital, LLC | 0.01% | Add +5.0% | 156,000 | $549K |
| Vanguard Group Inc. | 0.00% | Add +12.1% | 84,418 | $297K |
| LPL Financial LLC | 0.00% | New | 33,754 | $119K |
| Geode Capital Management, LLC | 0.00% | Add +19.0% | 19,756 | $69K |
| BlackRock Inc. | 0.00% | Add +0.0% | 12,475 | $44K |
| Atticus Wealth Management, LLC | 0.00% | No change | 3,334 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +221.3% | 1,995 | $7K |
| NFSG Corp | 0.00% | Add +99.6% | 1,367 | $5K |
| Morgan Stanley | 0.00% | Add +0.7% | 426 | $2K |
| Sandy Spring Bank | 0.00% | No change | 89 | $314 |
| CVA Family Office, LLC | 0.00% | No change | 34 | $120 |
| Bank of America Corp. | 0.00% | Add +300.0% | 28 | $99 |
| Osaic Holdings, Inc. | 0.00% | Reduce -64.6% | 23 | $81 |
| North Star Investment Management Corp. | 0.00% | Add +6.3% | 17 | $60 |
| JPMorgan Chase & Co. | 0.00% | Reduce -14.3% | 6 | $21 |
| Royal Bank of Canada | 0.00% | No change | 10 | $0 |
"% of holder's portfolio" is MBRX's weight in each manager's 13F, not the share of Moleculin Biotech Inc. the manager owns.